ResearcherUniversity of MichiganActive in the last 2 years
Hua Li
Matched on ORCID iD 0000-0003-2153-2500; OpenAlex author ID A5100344259. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 6
- Histone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling. Co-author DOI 10.1038/s41467-025-61197-z↗
- The UBE2F-CRL5ASB11-DIRAS2 axis is an oncogene and tumor suppressor cascade in pancreatic cancer cells. Co-author DOI 10.1016/j.devcel.2024.03.018↗
- Unlocking the Therapeutic Potential: Harnessing miR-125a-5p To Enhance Autophagy and Apoptosis in Pancreatic Cancer through Targeting STAT3. Co-author DOI 10.7150/jca.97102↗
- Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.1016/j.neo.2017.04.003↗
- DEPTOR has growth suppression activity against pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.2659↗
- Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. First author DOI 10.1158/0008-5472.can-11-2866↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yi Sun · 4 shared papers, 2012–2024 · strength 0.39
- Paper The UBE2F-CRL5ASB11-DIRAS2 axis is an oncogene and tumor suppressor cascade in pancreatic cancer cells. DOI 10.1016/j.devcel.2024.03.018↗
- Paper Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. DOI 10.1016/j.neo.2017.04.003↗
- Paper DEPTOR has growth suppression activity against pancreatic cancer cells. DOI 10.18632/oncotarget.2659↗
- Zongshuai Qin · 1 shared paper, 2024 · strength 0.24
- Lujuan Pan · 1 shared paper, 2024 · strength 0.24
- Yueqiu Qin · 1 shared paper, 2024 · strength 0.24
- Qian Chen · 1 shared paper, 2024 · strength 0.24
- Yu Chang · 1 shared paper, 2024 · strength 0.24
- Aziguli Tulamaiti · 1 shared paper, 2025 · strength 0.22
- Sang Lin · 1 shared paper, 2025 · strength 0.22
- Xueli Zhang · 1 shared paper, 2025 · strength 0.22
- Zhigang Zhang · 1 shared paper, 2025 · strength 0.22
- Xiaodong Zhao · 1 shared paper, 2025 · strength 0.22
- Edgar Ben‐Josef · 1 shared paper, 2014 · strength 0.04
- Mark M. Zalupski · 1 shared paper, 2014 · strength 0.04
- Theodore Steven Lawrence · 1 shared paper, 2012 · strength 0.03
- Meredith Ann Morgan · 1 shared paper, 2012 · strength 0.03
- Dongping Wei · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.